U.S. markets open in 3 hours 7 minutes
  • S&P Futures

    3,921.00
    +17.25 (+0.44%)
     
  • Dow Futures

    31,571.00
    +150.00 (+0.48%)
     
  • Nasdaq Futures

    12,082.75
    +42.25 (+0.35%)
     
  • Russell 2000 Futures

    1,781.70
    +11.90 (+0.67%)
     
  • Crude Oil

    111.34
    +1.77 (+1.62%)
     
  • Gold

    1,826.70
    +1.90 (+0.10%)
     
  • Silver

    21.28
    +0.12 (+0.55%)
     
  • EUR/USD

    1.0591
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.02
    -0.21 (-0.77%)
     
  • GBP/USD

    1.2264
    -0.0006 (-0.05%)
     
  • USD/JPY

    135.9410
    +0.4950 (+0.37%)
     
  • BTC-USD

    21,030.17
    -406.59 (-1.90%)
     
  • CMC Crypto 200

    459.17
    -2.63 (-0.57%)
     
  • FTSE 100

    7,344.64
    +86.32 (+1.19%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Why Leap Therapeutics Stock Is Surging Today

·2 min read
Why Leap Therapeutics Stock Is Surging Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Leap Therapeutics (NASDAQ: LPTX), a clinical-stage biopharmaceutical company, are surging in response to positive clinical results from a stomach cancer study. Last September, Leap Therapeutics stock more than doubled overnight after the company reported impressive response rate data for its lead candidate DKN-1 plus tislelizumab from BeiGene (NASDAQ: BGNE). The experimental combination treatment was tested among patients newly diagnosed with advanced-stage stomach cancer.